AXS-05 (dextromethorphan-bupropion) + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Agitation in Patients With Dementia of the Alzheimer's Type
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor
Trial Timeline
Jun 17, 2021 → Dec 21, 2024
NCT ID
NCT04947553About AXS-05 (dextromethorphan-bupropion) + Placebo
AXS-05 (dextromethorphan-bupropion) + Placebo is a phase 3 stage product being developed by Axsome Therapeutics for Agitation in Patients With Dementia of the Alzheimer's Type. The current trial status is completed. This product is registered under clinical trial identifier NCT04947553. Target conditions include Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04947553 | Phase 3 | Completed |
Competing Products
20 competing products in Agitation in Patients With Dementia of the Alzheimer's Type